Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00275262 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation
A Phase 2 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00275262 is a Phase 2 study that was terminated before completion, run by Abbott. The registered enrollment target is 25 participants.
The verdict
NCT00275262, a Phase 2 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
Phase 2 study, conducted in patients with Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or mantle cell lymphoma undergoing high-dose chemotherapy and autologous stem cell transplantation.
Interventions
- DRUG Matched placebo
- DRUG Leuprolide acetate depot (LAD) 11.25 mg 3 Month
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00275262
The ClinicalTrials.gov registry entry for NCT00275262 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matched placebo is the first listed.
NCT00275262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00275262 about?
NCT00275262 is a clinical study titled "A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation". Phase 2 study, conducted in patients with Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or mantle cell lymphoma undergoing high-dose chemotherapy and autologous stem cell transplantation.
What is the current status of trial NCT00275262?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2006-02.
What interventions are being tested in trial NCT00275262?
The interventions under investigation include: Matched placebo (DRUG), Leuprolide acetate depot (LAD) 11.25 mg 3 Month (DRUG).
Who is sponsoring clinical trial NCT00275262?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.